World Markets

Novartis licenses rights to RNA-targeting cardio drug from Ionis

Reuters

ZURICH, Feb 25 () - Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.

"We're excited about the novel, RNA-targeting approach that could be a gamechanger for people with elevated Lp(a)," said John Tsai, Novartis's drug development head. "If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option."

OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

ZURICH, Feb 25 () - Swiss drugmaker Novartis said on Monday it is exercising its option to license rights to an investigational, RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as it targets inherited factors that have defied other treatments.

"We're excited about the novel, RNA-targeting approach that could be a gamechanger for people with elevated Lp(a)," said John Tsai, Novartis's drug development head. "If our Phase 3 trial succeeds, we expect that TQJ230 will become the leading treatment option."


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IONS

Other Topics

Stocks Economy Commodities

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More